Fairness opinions › Acquirers
Abbott Laboratories: healthcare acquisitions with fairness opinions
2 public-company targets, 2016-2017, $36B combined enterprise value. The multiples Abbott Laboratories paid and the banker analyses behind each target board's recommendation.
Deals
2
Median EV / EBITDA paid
14.8x
Median EV / revenue paid
3.83x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2017-04-14 | Alere | Abbott Laboratories | Diagnostics / Life Sciences | $7.1B | 14.3x | 2.95x | 8.3%–9.8% | J.P. Morgan |
| 2016-04-28 | St. Jude Medical | Abbott Laboratories | Medical Devices and Supplies | $29B | 15.2x | 4.70x | 7.0%–8.5% | Guggenheim Securities |